P1, N=35, Completed, Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting --> Completed

P2, N=108, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability...In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.

Standard chemotherapy regimens for patients with breast cancer are based on epirubicin-cyclophosphamide (EC) and paclitaxel (TAX) administrations. In only 4 days, the first TAX administration induced severe skeletal muscle mitochondrial remodelling in patients with breast cancer, characterized by impaired mitochondrial dynamics that resulted in swollen and damaged organelles. These findings demonstrate that mitochondrial toxicity, classically documented at the end of treatment, occurs acutely and after only one chemotherapy administration.

P2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027

Furthermore, these derivatives displayed higher selectivity for cancer cells over normal cells (SI > 44) compared to the positive controls, doxorubicin (SI > 2) and cisplatin (SI = 5). Molecular docking analysis indicated that these compounds (6a and 7b) form interactions with the aurora A kinase receptor both from structural and energetic perspectives. These results suggest that derivatives 6a and 7b have potential for further development as aurora A kinase inhibitors for colorectal cancer treatment.

The SCLC component dictated adjuvant cisplatin-etoposide regardless of the accompanying adenocarcinoma histology. This case report exemplifies the importance of integrated histologic and molecular evaluation, and the need to recognize potentially actionable mutations in combined SCLC. Comprehensive profiling not only clarifies clonal relationships and may guide therapeutic strategies, including in the context of recurrence or combined presentations.

Here, we develop soft hybrid microparticles (3D-PMPs) by fusing tumor-repopulating cell-derived microparticles with inactivated platelet membranes to deliver the anticancer agent doxorubicin (DOX@3D-PMPs)...DOX@3D-PMPs demonstrate significantly enhanced therapeutic efficacy in both orthotopic 4T1 breast tumors and post-surgical orthotopic 4T1 breast tumors. This work offers a novel and effective approach to enhance the therapeutic outcomes in cancer treatment, particularly in post-surgical settings.

In Huh7 cells, it suppressed TAp63/Bax-mediated apoptosis while driving both oxidative phosphorylation and glycolysis, promoting resistance despite the absence of wild-type p53. These findings identify miR-203a-3p as a key modulator of DOX resistance in HCC through coordinated regulation of p53 family expression, apoptotic signaling, and metabolic rewiring, highlighting its potential as a therapeutic target for miRNA-based combination therapies.

In anti-diabetic assays, LREEs dose-dependently inhibited α-amylase and α-glucosidase, although less potent than acarbose. Cytotoxicity testing on HepG2 cancer cells showed an IC50 of 281.80 µg/mL, significantly higher than doxorubicin (34.07 µg/mL), indicating weak anticancer potential...The investigated material was evaluated as a mixed light rare earth oxide system to obtain an integrated biological response profile rather than to determine the contribution of individual oxide components. Therefore, the present findings represent system-level biological behaviour and serve as a foundation for more detailed component-specific investigations.

Importantly, LMP-associated doxorubicin redistribution was accompanied by increased intracellular retention and nuclear accumulation of doxorubicin; in parallel, decreased P-glycoprotein (P-gp/ABCB1) levels and a reduced drug-efflux phenotype were observed. These effects correlate with improved antitumor efficacy in vitro and in vivo. Overall, these results support tandem enzyme-guided intracellular self-assembly as a supramolecular route to chemosensitization.

P2, N=60, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> May 2026